Evidence map›Paper›PMID 27703782›Full record

ArticleBJPsych open2016

Ketamine: stimulating antidepressant treatment?

Gin S Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A Frye, Michael Gitlin, Sidney H Kennedy, Terence A Ketter, Raymond W Lam and 6 more

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Intranasal Esketamine (SpravatoP & T : a peer-reviewed journal for formulary management · 2019
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 16 institutions in 5 countries.

Gin S Malhi, MD, Department of Psychiatry, Kolling Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia.
Yulisha Byrow, PhD, CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia.
Frederick Cassidy, MD, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
Andrea Cipriani, PhD, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
Koen Demyttenaere, PhD, KU Leuven, Department of Neurosciences, Research Group of Psychiatry, University Psychiatric Center, Leuven, Belgium.
Mark A Frye, MD, Psychiatry, Mayo Clinic Depression Center, Mayo Clinic, Rochester, MN, USA.
Michael Gitlin, MD, Department of Psychiatry, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sidney H Kennedy, MD, Arthur Sommer Rotenberg Chair in Suicide & Depression Studies, St. Michael's Hospital; Professor of Psychiatry, University Health Network and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Terence A Ketter, MD, Psychiatry and Behavioral Sciences, Chief, Bipolar Disorders Clinic, Stanford University School of Medicine, Stanford, CA, USA.
Raymond W Lam, MD, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Rupert McShane, MD, Oxford Health NHS Foundation Trust, Oxford, UK.
Alex J Mitchell, MD, Liaison Psychiatry and Psycho-Oncology, University of Leicester, Leicester, UK.
Michael J Ostacher, MD, Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Sakina J Rizvi, PhD, Li Ka Shing Knowledge Institute, ASR Suicide and Depression Studies Program, St. Michael's Hospital; Department of Psychiatry and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Michael E Thase, MD, Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
Mauricio Tohen, MD, Professor and Chairman of the Department of Psychiatry & Behavioural Sciences at the University of New Mexico, Albuquerque, NM, USA.
Duke University · USKU Leuven · BEMayo Clinic in Arizona · USOxford Health NHS Foundation Trust · GBRoyal North Shore Hospital · AUStanford University · USSt Michaels Hospital · GBSt. Michael's Hospital · CAThe University of Sydney · AUUniversity of British Columbia · CAUniversity of California, Los Angeles · USUniversity of Leicester · GBUniversity of New Mexico · USUniversity of Pennsylvania · USVA Palo Alto Health Care System · USWarneford Hospital · GB

Funding

Department of Health PB-PG-0408-16030
6 · The paper itself

Abstract

summaryThe appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations. DECLARATION OF INTERESTS: COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.

Identifiers

PMID27703782
PMCPMC4995167
OpenAlexW2385546112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.